Atrial Septal Defect (ASD) Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Children and adults with a confirmed secundum ASD with a stretched diameter of 5–38 mm, adequate septal rims (≥5 mm on most rims), and a Qp:Qs ratio >1.5:1 are ideal candidates for transcatheter Amplatzer or equivalent device closure.

• Patients with primum ASD, sinus venosus ASD, or ASD associated with partial anomalous pulmonary venous return (PAPVR) who require surgical repair under cardiopulmonary bypass.

• Symptomatic patients (dyspnea on exertion, fatigue, recurrent respiratory infections, failure to thrive in pediatric patients) regardless of defect size where hemodynamically significant shunting is confirmed.

• Asymptomatic adults with echocardiographic evidence of right ventricular volume overload (RV end-diastolic dimension above the 95th percentile for age) per AHA/ACC Class I indications.

• Patients with cryptogenic stroke or TIA attributed to paradoxical embolism through a confirmed significant ASD or PFO-ASD spectrum defect.

• Adults with new-onset atrial fibrillation or flutter where ASD-related right atrial dilation is the identified substrate.

• REQUIRED DIAGNOSTIC WORKUP:

• Transthoracic Echocardiography (TTE): First-line imaging to identify defect location, size, direction and magnitude of shunt, and right ventricular function.

• Transesophageal Echocardiography (TEE) or Intracardiac Echocardiography (ICE): Mandatory pre-procedural assessment for defect morphology, rim adequacy, and device sizing.

• Three-Dimensional Echocardiography (3D-TEE): Increasingly used for precise en-face visualization and device sizing in complex defects.

• Cardiac MRI (CMR): Definitive Qp:Qs quantification, volumetric assessment of biventricular function, and detection of anomalous pulmonary veins in sinus venosus ASD.

• Right Heart Catheterization (RHC): Mandatory when pulmonary arterial hypertension is suspected; measures pulmonary vascular resistance (PVR) and response to vasodilators.

• Chest X-Ray: Assessment of cardiomegaly, pulmonary plethora, and right atrial/ventricular prominence.

• 12-Lead ECG: Detection of right bundle branch block (rSR' pattern in V1), right axis deviation, and arrhythmia burden.

• Complete Blood Count, Coagulation Profile (PT/INR, aPTT), Renal and Liver Function Tests: Standard pre-procedural clearance.

• CT Pulmonary Angiography (CTPA): Required for precise delineation of pulmonary venous anatomy in sinus venosus ASD planning.

• CONTRAINDICATIONS:

• Eisenmenger syndrome with irreversible pulmonary arterial hypertension (PVR >5 Wood units unresponsive to vasodilator testing) — closure is contraindicated as it may precipitate acute right heart failure.

• Deficient or absent septal rim anatomy (particularly deficient aortic or posterior rims <5 mm on multiple aspects) making transcatheter closure technically non-feasible; surgical repair is the alternative.

• Active systemic infection or sepsis prior to elective closure.

• Uncorrected significant coagulopathy or thrombocytopenia (platelet count <50,000/µL) that cannot be optimized pre-procedurally.

• Known allergy or hypersensitivity to nitinol (nickel-titanium alloy) — relevant to all nitinol-based occluder devices.

• Anatomy unsuitable for femoral venous access (e.g., interrupted inferior vena cava without alternative access planning).

TRANSCATHETER DEVICE CLOSURE (First-Line for Eligible Secundum ASD)

Transcatheter closure under TEE or ICE guidance via femoral venous access is the preferred approach for secundum ASDs with adequate rims and a stretched diameter up to approximately 38–40 mm. The Amplatzer Septal Occluder (ASO, Abbott) is the most extensively studied device, with over two decades of follow-up data demonstrating closure rates of 96–98% at one year. Alternative CE-marked and FDA-approved devices include the Occlutech Figulla Flex II, the Gore Cardioform Septal Occluder (preferred when aortic rim is deficient due to its pliable design), and the Lifetech CeraFlex in select centers. The procedure is performed under general anesthesia or conscious sedation, typically takes 45–90 minutes, and involves: femoral venous cannulation → transseptal sheath advancement → balloon sizing of the defect → device deployment under real-time imaging → confirmation of device position and residual shunt by color-flow Doppler TEE → sheath withdrawal. Patients receive aspirin (3–5 mg/kg/day, maximum 100 mg/day) for six months post-procedure and clopidogrel for three months in most institutional protocols. ICE-guided closure without general anesthesia is increasingly performed in adult patients at high-volume centers, reducing anesthetic risk and hospital stay to a single overnight observation.

MINIMALLY INVASIVE SURGICAL REPAIR (Video-Assisted / Robotic-Assisted)

For anatomically complex ASDs unsuitable for transcatheter closure — including primum, sinus venosus, and large secundum defects with deficient rims — minimally invasive surgical repair via right anterolateral mini-thoracotomy (3–4 cm incision) under cardiopulmonary bypass (CPB) has become the standard at high-volume centers. This approach avoids full sternotomy, reduces blood loss, shortens ICU stay to 24–48 hours, and results in superior cosmesis. Cardiopulmonary bypass is established via peripheral (femoral or direct aortic/caval) cannulation. Surgical techniques include:

• Primary suture closure: Suitable for small to moderate secundum defects with adequate tissue margins.

• Pericardial patch repair (autologous or bovine pericardium): Standard for large secundum, all primum (with concurrent mitral cleft repair if required), and sinus venosus ASDs.

• Anomalous pulmonary vein re-implantation or Warden procedure: Applied in sinus venosus ASD with PAPVR to redirect pulmonary venous drainage to the left atrium.

ROBOTIC-ASSISTED CARDIAC SURGERY (Da Vinci System)

Select centers in India (Narayana Health, Apollo Hospitals, Fortis Malar) and the UAE (Cleveland Clinic Abu Dhabi) offer robotic-assisted ASD repair using the da Vinci Surgical System, enabling precise endoscopic repair through 8–12 mm port incisions with 3D magnified visualization. This approach is associated with zero sternotomy trauma, minimal blood transfusion requirements, and accelerated return to full activity (3–4 weeks versus 6–8 weeks for open sternotomy). Patient selection requires specific anatomical suitability and surgeon expertise.

HYBRID PERVENTRICULAR CLOSURE

For small infants and patients in whom standard transfemoral access is challenging due to vascular size constraints, some pediatric cardiac centers perform hybrid perventricular closure — a transesophageal-guided, off-bypass technique where the device is deployed directly through the right ventricular wall via a limited subxiphoid incision. This avoids femoral vessel injury and cardiopulmonary bypass in selected small patients.

MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN BORDERLINE CASES

In patients with borderline or moderate PAH (PVR 3–5 Wood units), a time-limited trial of targeted PAH pharmacotherapy — including phosphodiesterase-5 inhibitors (sildenafil, tadalafil) or endothelin receptor antagonists (bosentan) — may be prescribed for 3–6 months prior to reassessment for ASD closure eligibility. This 'treat-and-repair' strategy has demonstrated PVR reduction sufficient to enable safe closure in a subset of patients who would otherwise be deemed inoperable.

PHASE 1 — PRE-ARRIVAL & CONSULTATION (Weeks 1–3 before travel)

• GAF Healthcare case manager reviews patient records, echocardiography reports, and prior investigations submitted via secure online portal.

• Virtual consultation with a shortlisted congenital/adult congenital cardiologist at the chosen India or UAE center is arranged within 48–72 hours.

• Cardiologist issues a formal opinion confirming candidacy for transcatheter or surgical closure and specifies which additional investigations (if any) are required on arrival.

• GAF Healthcare assists with e-Medical visa application for India (typically approved within 24–72 hours) or UAE entry visa/visa-on-arrival processing, and arranges airport transfer, accommodation, and hospital appointment scheduling.

PHASE 2 — ARRIVAL & PRE-PROCEDURAL WORKUP (Days 1–2 in-country)

• Day 1: Airport pickup by GAF Healthcare representative; hotel or hospital guesthouse check-in; rest.

• Day 2: Hospital admission or outpatient pre-assessment. Investigations completed on arrival typically include: TTE and/or TEE, 12-lead ECG, Chest X-Ray, complete blood count, coagulation profile, renal/liver function tests, blood typing and crossmatching, anesthesia fitness assessment, pediatric or adult cardiology consultation, and cardiac surgery consultation if open repair is planned. For sinus venosus ASD, CT pulmonary angiography or cardiac MRI is performed at this stage.

• Anesthesiologist review and pre-operative counseling by the surgical/catheterization team.

• Written informed consent obtained with multilingual support arranged by GAF Healthcare interpreter.

PHASE 3 — THE PROCEDURE (Day 3)

FOR TRANSCATHETER CLOSURE:

• Patient is fasted from midnight. General anesthesia or conscious sedation is administered.

• Femoral venous access is secured; right heart catheterization performed to confirm Qp:Qs and rule-out significant PAH.

• Defect sizing by balloon occlusion or direct 3D-TEE measurement.

• Appropriate device selected and deployed under continuous real-time TEE and fluoroscopic guidance.

• Post-deployment assessment: device stability, disc position, residual shunting (none or trivial confirmed), AV valve and pulmonary vein flow unobstructed.

• Procedure duration: 60–120 minutes. Recovery room observation: 2–4 hours.

FOR OPEN / MINIMALLY INVASIVE SURGICAL REPAIR:

• General anesthesia induction; arterial and central venous lines placed.

• Surgical access: right anterolateral mini-thoracotomy or full median sternotomy depending on defect complexity.

• Cardiopulmonary bypass established; heart arrested with cardioplegic solution (del Nido or St Thomas crystalloid cardioplegia).

• Right atriotomy performed; defect repaired by primary suture or pericardial patch.

• Associated lesions corrected concurrently (mitral cleft repair in primum ASD, Warden procedure for PAPVR).

• CPB weaned; de-airing performed; right atrium closed; cardiac rhythm and hemodynamics confirmed.

• Chest drain placed; incision closed in layers.

• Procedure duration: 2–4 hours. Transfer to pediatric or adult cardiac ICU.

PHASE 4 — IMMEDIATE POST-PROCEDURAL RECOVERY (Days 3–7)

TRANSCATHETER:

• Overnight in-hospital observation monitoring cardiac rhythm (telemetry), device position (chest X-ray), and vascular access site.

• Discharge on Day 2 (post-procedure Day 1) with aspirin ± clopidogrel and activity restrictions.

• Follow-up TTE before discharge to confirm device position and closure.

SURGICAL:

• ICU: 24–48 hours. Extubation typically within 4–8 hours post-operatively for uncomplicated cases.

• Chest drains removed on post-operative Day 1–2.

• Step-down cardiac ward Days 2–5; cardiac physiotherapy commenced (breathing exercises, supervised ambulation).

• Hospital discharge on post-operative Day 5–7 following TTE confirmation of repair integrity.

PHASE 5 — RECOVERY & FIT-TO-FLY PERIOD (Weeks 1–6 post-procedure)

• TRANSCATHETER CLOSURE: Patients are advised to remain in-country for 2–3 weeks post-procedure. During this period, follow-up TTE at Day 7–10 and clinical cardiology review confirm device endothelialization is progressing and no device embolization or erosion has occurred. Light activity is resumed at Week 2; strenuous exertion avoided for 6 months.

• SURGICAL REPAIR: Patients are advised to remain in-country for 4–6 weeks. Sternal/thoracotomy wound healing is assessed at Week 4; sutures or staples removed at Week 2. Physical milestones: independent ambulation by Day 5–7; climbing stairs by Week 2–3; return to light daily activities by Week 4; full unrestricted activity (for adults) by 8–12 weeks.

• ANTICOAGULATION / ANTIPLATELET MONITORING: Post-device-closure patients are maintained on aspirin for 6 months with INR monitoring if anticoagulation is co-prescribed for concurrent atrial fibrillation. Surgical patients receive short-course prophylactic anticoagulation per institutional protocol.

• ENDOCARDITIS PROPHYLAXIS: Recommended for 6 months following device closure (until complete endothelialization confirmed) and for all patients with residual defects or prior endocarditis history.

• FINAL CLEARANCE: Formal fit-to-fly letter issued by treating cardiologist following final pre-departure echocardiogram and clinical review. Patients traveling long-haul are advised on in-flight hydration, compression stockings, and periodic ambulation to minimize thromboembolism risk.